Home / News / FAQ
FAQ

FAQ on Quantum BioPharma Ltd.'s Expansion of unbuzzd Through AATAC Retail Deal

FaqStaq News - Just the FAQs • April 15, 2025
By FAQstaq Staff
Read Original Article →
FAQ on Quantum BioPharma Ltd.'s Expansion of unbuzzd Through AATAC Retail Deal

Summary

Quantum BioPharma Ltd. (NASDAQ: QNTM) has expanded the retail reach of its product unbuzzd, a beverage aimed at reducing blood alcohol levels, through a strategic partnership between its licensee Celly Nutrition Corporation and the Asian American Trade Associations Council (AATAC), leveraging AATAC's extensive network of over 80,000 retail locations.

What is unbuzzd and what does it aim to do?

unbuzzd is a beverage aimed at reducing blood alcohol levels and restoring mental clarity, developed by Quantum BioPharma Ltd. and now being expanded through a retail partnership.

How is Quantum BioPharma Ltd. expanding the reach of unbuzzd?

Through a strategic partnership between its licensee, Celly Nutrition Corporation, and the Asian American Trade Associations Council (AATAC), unbuzzd’s ‘On-the-Go Powder Stick Packs’ will be promoted across AATAC’s network of over 80,000 retail locations.

What is the significance of the AATAC retail deal for unbuzzd?

The deal is expected to significantly boost sales and consumer reach of unbuzzd in the health and wellness space by leveraging AATAC’s vast retail network, including major chains like 7-Eleven, Shell, and Chevron.

What does Quantum BioPharma Ltd. specialize in?

Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, including alcohol misuse disorders, with drug candidates in various stages of development.

Lucid-MS is a patented new chemical entity developed by Quantum BioPharma’s subsidiary, Lucid Psycheceuticals Inc., shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.

How does Quantum BioPharma Ltd. benefit from the unbuzzd sales?

Quantum BioPharma retains ownership of 25.71% of Celly Nutrition as of June 30, 2024, and receives royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity.

Where can I find more information about Quantum BioPharma Ltd. and its developments?

The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.

What is the role of Celly Nutrition Corporation in the unbuzzd product?

Celly Nutrition Corporation, led by industry veterans, is the licensee to which Quantum BioPharma spun out the OTC version of unbuzzd, and is responsible for its retail expansion through partnerships like the one with AATAC.

QR Code for Content Provenance

This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)

Article Control ID: 122310